Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
$0.01
$0.01
$0.02
$1.19M-0.92435,993 shs39,482 shs
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
$11.90
+1.0%
$12.39
$7.30
$15.50
$595.60M-0.04492,167 shs338,543 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.61
-0.4%
$4.22
$3.52
$7.63
$1.09B0.962.44 million shs1.74 million shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.26
-0.8%
$1.39
$1.12
$2.55
$61.31M0.436,369 shs68,347 shs
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$0.23
$0.06
$1.35
$1.87M2.183.66 million shs29.90 million shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00%+6.38%+4.17%+3.09%+4.71%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
0.00%+4.29%-13.77%+11.11%+1.54%
MannKind Corporation stock logo
MNKD
MannKind
0.00%-4.12%-16.16%-23.95%-28.33%
MediciNova, Inc. stock logo
MNOV
MediciNova
0.00%-5.26%-9.68%+1.61%-10.00%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00%0.00%0.00%0.00%-91.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.5955 of 5 stars
0.03.00.04.80.00.00.0
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
4.1625 of 5 stars
3.61.00.04.42.42.50.6
MannKind Corporation stock logo
MNKD
MannKind
2.5801 of 5 stars
3.61.00.00.00.71.71.9
MediciNova, Inc. stock logo
MNOV
MediciNova
1.8524 of 5 stars
3.82.00.00.00.00.80.0
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
3.13
Buy$24.83108.68% Upside
MannKind Corporation stock logo
MNKD
MannKind
3.29
Buy$10.33186.64% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
3.50
Strong Buy$7.00455.56% Upside
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest KALV, VBIV, MNKD, MNOV, and EVFM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00
4/10/2025
MannKind Corporation stock logo
MNKD
MannKind
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
4/9/2025
MannKind Corporation stock logo
MNKD
MannKind
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/9/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/8/2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.10N/AN/A($2.64) per share0.00
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/AN/AN/AN/A$4.86 per shareN/A
MannKind Corporation stock logo
MNKD
MannKind
$297.60M3.68$0.14 per share25.94($0.29) per share-12.43
MediciNova, Inc. stock logo
MNOV
MediciNova
$1M61.80N/AN/A$1.07 per share1.18
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$9.41M0.00N/AN/A$0.32 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.05N/AN/A-46.42%-91.97%-61.93%N/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$126.64M-$3.72N/AN/AN/AN/A-104.25%-78.69%7/10/2025 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$27.59M$0.1036.0515.67N/A10.12%-32.41%10.85%8/6/2025 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
-$92.84MN/A0.00N/AN/A-881.79%-525.42%-45.87%N/A

Latest KALV, VBIV, MNKD, MNOV, and EVFM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/10/2025Q4 2025
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$0.83N/AN/AN/AN/AN/A
5/13/2025Q1 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.14-$0.06+$0.08-$0.06N/AN/A
5/8/2025Q1 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.03$0.04+$0.01$0.04$75.86 million$78.35 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/A
10.44
10.44
MannKind Corporation stock logo
MNKD
MannKind
N/A
2.36
2.11
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
17.66
17.66
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/A
0.34
0.21

Institutional Ownership

CompanyInstitutional Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/A
MannKind Corporation stock logo
MNKD
MannKind
49.55%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
12.26%

Insider Ownership

CompanyInsider Ownership
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.21%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
10.50%
MannKind Corporation stock logo
MNKD
MannKind
2.70%
MediciNova, Inc. stock logo
MNOV
MediciNova
13.60%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
10.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120118.66 million113.12 millionNot Optionable
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
10049.72 million44.50 millionOptionable
MannKind Corporation stock logo
MNKD
MannKind
400303.93 million295.73 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.05 million42.38 millionOptionable
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
2228.68 million25.71 millionOptionable

Recent News About These Companies

VBI recalls PreHevbrio and winds down operations
Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
VBI craters as investors react to Hep B vaccine data
VBI Vaccines Reports Full Year 2023 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.01 0.00 (0.00%)
As of 07/3/2025 11:39 AM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

KalVista Pharmaceuticals stock logo

KalVista Pharmaceuticals NASDAQ:KALV

$11.90 +0.12 (+1.02%)
Closing price 07/3/2025 03:53 PM Eastern
Extended Trading
$12.04 +0.14 (+1.21%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

MannKind stock logo

MannKind NASDAQ:MNKD

$3.60 -0.02 (-0.41%)
Closing price 07/3/2025 03:48 PM Eastern
Extended Trading
$3.61 +0.00 (+0.14%)
As of 07/3/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.26 -0.01 (-0.79%)
As of 07/3/2025 01:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

VBI Vaccines stock logo

VBI Vaccines NASDAQ:VBIV

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.